Literature DB >> 35426495

Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software.

Soumya Mukherjee1, John C Fjeldsted2, Colin L Masters3, Blaine R Roberts4,5.   

Abstract

Isomerization of aspartic acid (Asp) residues in long-lived proteins is a key feature associated with neurodegenerative proteinopathies such as Alzheimer's disease (AD). Recently, using ultra high-performance liquid chromatography (UHPLC) coupled with drift tube ion mobility mass spectrometry (DTIMS-MS), we documented the extensive Asp isomerization in amyloid-beta (Aβ) peptides depositing in the extracellular cortical plaques (senile plaques) of the AD brain. Aβ1-15 was estimated to be ~ 85% isomerized, while Aβ4-15 another major constituent of these senile plaques was ~ 50% isomerized in AD brain. Low resolution on the standard demultiplexed ion mobility resulted in poor separation of these N-truncated Aβ isomers in the ion mobility domain. Here, using the same ion multiplexed dataset, we applied new post-acquisition data reconstruction technique, high-resolution demultiplexing (HRdm), to improve the resolution of these Aβ isomers in the ion mobility dimension. We demonstrate that for the complex proteomic AD brain digests, HRdm could successfully resolve three out of four major Asp isomers of Aβ1-15. For Aβ2-15 and Aβ4-15, the significant resolution enhancement in the HRdm data resulted in baseline peak separation of the respective Asp isomers. An analysis of two-peak resolution (Rpp) and peak-to-peak separation (ΔP) indicated twofold enhancement for the Asp-isomerized Aβ species. HRdm performed with an effective resolving power (Rp) of between 150 and 160 for the highest deconvolution settings in comparison to ~ 40 to 65 in the standard settings. These major resolution improvements in the ion mobility domain for the endogenous Aβ isomers demonstrate the feasibility of in situ measurement of peptide isomers and their role in the mechanism of amyloid plaque formation in AD.
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Aβ isomers; High-resolution demultiplexing (HRdm); Ion mobility separation (IMS)

Mesh:

Substances:

Year:  2022        PMID: 35426495     DOI: 10.1007/s00216-022-04055-x

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  41 in total

1.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

Review 2.  Autophagy failure in Alzheimer's disease--locating the primary defect.

Authors:  Ralph A Nixon; Dun-Sheng Yang
Journal:  Neurobiol Dis       Date:  2011-02-03       Impact factor: 5.996

3.  Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Authors:  Kwasi G Mawuenyega; Wendy Sigurdson; Vitaliy Ovod; Ling Munsell; Tom Kasten; John C Morris; Kevin E Yarasheski; Randall J Bateman
Journal:  Science       Date:  2010-12-09       Impact factor: 47.728

4.  Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET.

Authors:  Blaine R Roberts; Monica Lind; Aaron Z Wagen; Alan Rembach; Tony Frugier; Qiao-Xin Li; Timothy M Ryan; Catriona A McLean; James D Doecke; Christopher C Rowe; Victor L Villemagne; Colin L Masters
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

5.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

6.  Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms.

Authors:  M Goedert; M G Spillantini; N J Cairns; R A Crowther
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

7.  Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.

Authors:  H Mori; K Takio; M Ogawara; D J Selkoe
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

8.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

9.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

Review 10.  APP processing in Alzheimer's disease.

Authors:  Yun-wu Zhang; Robert Thompson; Han Zhang; Huaxi Xu
Journal:  Mol Brain       Date:  2011-01-07       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.